Telotristat Plus Everolimus Halts Tumor Growth in Neuroendocrine Cancer Models

Neuroendocrine tumors, a rare and heterogeneous family of neoplasms that arise in hormone-producing cells throughout the body, have long posed a treatment puzzle: the drugs that control their debilitating symptoms are not always the drugs that shrink their tumors. A new preclinical study published in Drugs in R&D now reports that pairing a symptom-directed drug with a cancer-directed drug produced a strikingly stronger effect than either agent alone, at least in laboratory models of the disease.

The drug in question, telotristat ethyl, blocks tryptophan hydroxylase, the rate-limiting enzyme in serotonin synthesis. It was developed to tame carcinoid syndrome, the constellation of diarrhea, flushing and carcinoid heart disease driven by serotonin overproduction in neuroendocrine tumor patients. In the phase III TELESTAR trial, telotristat ethyl significantly improved bowel-movement control in patients whose carcinoid syndrome remained inadequately controlled despite somatostatin analog therapy. What has remained unclear is whether the drug does anything to the tumor itself. Only one small retrospective case series has hinted at possible antitumor activity, and telotristat ethyl has not yet been evaluated for direct antitumor effects in human clinical trials.

The research team, led by investigators from Spanish and international institutions, set out to test whether telotristat ethyl could kill neuroendocrine tumor cells directly, and whether it might work better in combination with established therapies. They worked with three human neuroendocrine tumor cell lines: BON-1 and QGP-1, both derived from pancreatic tumors, and HROC57, derived from an intestinal tumor. The cells were treated for 72 hours with telotristat ethyl alone, with everolimus, an orally available inhibitor of the mTOR signaling pathway, with the somatostatin analog octreotide, with serotonin itself, with the chemotherapy pair capecitabine and temozolomide, and with the multi-kinase inhibitor sunitinib, both alone and in combinations.

The results were unambiguous at the cellular level. Telotristat ethyl reduced cell viability in all three lines, with half-maximal inhibitory concentrations of 20.71 micromolar in BON-1, 23.71 micromolar in QGP-1 and 11.43 micromolar in HROC57. Octreotide, by contrast, left viability untouched, and adding serotonin produced only a mild viability increase in QGP-1 and HROC57 cells. Capecitabine plus temozolomide, a combination associated with durable responses in metastatic pancreatic endocrine carcinomas in the clinic, failed to affect any of the tested lines. Sunitinib was effective across the board, but when paired with telotristat it offered no advantage over sunitinib alone. Everolimus reduced viability most strongly in the pancreatic lines and only weakly in the more resistant HROC57 cells.

The pivotal finding emerged when telotristat was combined with everolimus. Across all three cell lines, the pairing produced a clear synergistic reduction in cell viability, an effect the authors note would formally require dedicated pharmacologic modeling to confirm as true synergy, but which was visibly stronger than either drug alone. Flow-cytometry analysis of BON-1 and HROC57 cells stained with annexin V and propidium iodide showed that the combination was the most efficient strategy for decreasing live cells and increasing both early and late apoptotic populations. Cell-cycle profiling added a mechanistic clue: telotristat or everolimus alone tended to push cells into the G2/M phase, while the combination markedly depleted that compartment, suggesting the drug pair is especially lethal to cells at mitosis even though neither agent targets mitotic machinery directly.

Signaling analysis in cultured BON-1 cells revealed an unexpected twist. Everolimus, as expected, strongly suppressed the mTOR pathway, but it simultaneously activated the MAPK and AKT pathways, most likely through a feedback loop triggered by mTOR blockade. The combination with telotristat amplified that feedback activation even further. The authors interpret this as evidence that tryptophan hydroxylase inhibition adds a second cellular stress that converges on the mitotic stage, though they acknowledge that the precise molecular mechanism by which the two drugs cooperate remains unknown and merits further research.

To test whether the cellular findings would translate to living tissue, the team implanted mice with subcutaneous xenografts of BON-1 cells engineered to express red fluorescent protein. Once tumors reached an average volume of 100 cubic millimeters, animals were assigned to four groups receiving vehicle, telotristat at 200 milligrams per kilogram per day, everolimus at 5 milligrams per kilogram per day, or both drugs together, all delivered by daily oral gavage five days a week for roughly 30 days. Both single agents slowed tumor growth to a similar degree. The combination, however, practically blocked tumor growth for the entire treatment period and was the only strategy that significantly reduced the area under the growth curve, final tumor volume and tumor weight at sacrifice. Fluorescence imaging of the red-fluorescent tumors confirmed the same pattern.

Examination of the excised tumors explained the growth arrest. Immunohistochemistry showed that single-agent treatment significantly reduced proliferation as measured by Ki67 staining, and the combination maintained that same reduced proliferation while adding a strong increase in apoptosis detected by active caspase-3 staining. Western blots of tumor lysates showed reduced CYCLIN-D1 and increased p21 across treatments, decreased p53 levels that the authors attribute to its mutant status in BON-1 cells, reduced levels of the anti-apoptotic protein BCL-XL, and increased expression of the epithelial marker E-cadherin, a protein whose loss is associated with more aggressive neuroendocrine tumors. Notably, the enhanced MAPK and AKT activation seen in cultured cells did not appear in the tumors, a discrepancy the authors flag between the in vitro and in vivo settings.

Toxicity monitoring offered cautious reassurance within the limits of the model. Mice in all treatment groups, including the combination arm, showed no loss of body weight; the combination group actually gained slightly. Red blood cell and platelet parameters were unchanged. White blood cells, lymphocytes and monocytes declined with all treatments, most markedly with the combination, but none of the hematological values reached pathological thresholds. Large necrotic areas were observed in tumors from all treatment groups, and these were largest in the combination arm, consistent with the drug pair’s cytotoxic effect on the tumor tissue itself.

The authors are careful about what these results do and do not establish. Telotristat ethyl showed antitumor activity in their models, consistent with inhibition of serotonin biosynthesis, but the relative contribution of serotonin depletion versus other mechanisms remains to be determined, particularly since earlier work by other groups found that telotristat potently suppresses serotonin secretion with only limited effects on proliferation in certain in vitro models. The combination outperformed both single agents in vitro and in vivo with no major toxicity signals, but the work rests on three cell lines and a single BON-1 xenograft model in immunodeficient mice, and the drugs were tested at doses previously reported as safe and efficient in animal studies rather than at clinically validated combination schedules. The findings, the team concludes, open a clinical window of opportunity that should now be explored in trials involving neuroendocrine tumor patients, since both telotristat ethyl and everolimus are already used in clinical practice for other indications and could, in principle, be combined without the usual barrier of first-in-human safety testing.

Subject of Research: Preclinical evaluation of telotristat ethyl combined with everolimus against neuroendocrine tumors

Article Title: A Combination of the Tryptophan Hydroxylase Inhibitor Telotristat with the mTOR Inhibitor Everolimus as an Effective Strategy Against Neuroendocrine Tumors

Article References: Molina-Cerrillo, J., Sierra-Ramirez, A., López-Aceituno, J. L., Méndez-Pertuz, M., Alonso-Gordoa, T., Linnebacher, M., Santoni, M., Fernandez-Marcos, P. J., & Grande, E. (2026). A Combination of the Tryptophan Hydroxylase Inhibitor Telotristat with the mTOR Inhibitor Everolimus as an Effective Strategy Against Neuroendocrine Tumors. Drugs in R&D, 26(2), 155-167. https://doi.org/10.1007/s40268-026-00544-x

Image Credits: AI Generated

DOI: 10.1007/s40268-026-00544-x

Keywords: neuroendocrine tumors, telotristat ethyl, everolimus, tryptophan hydroxylase, serotonin, mTOR inhibition, xenograft model, apoptosis, carcinoid syndrome, drug combination, preclinical study, BON-1